Late-breaking trials on latest-generation aortic valves and dedicated transcatheter devices

Session comprising selected PCR London Valves 2023 Late-Breaking Trial submissions

Anchorperson: S. Windecker

Spokesperson: A. Baumbach

Summary

Find out the outcomes of the main studies on the latest-generation valves and devices presented at PCR LV 2023 to better determine their benefits, performance and interest in the treatment of specific aortic pathologies: REACCESS-2 Study, ACURATE Neo2 PMCF post-market registry, OCEAN-TAVI registry, ShortCut Pivotal Study, and much more!

Presentations available when logged in:

ShortCut™ Pivotal Study Update: Dedicated Transcatheter Leaflet Splitting Device
Coronary cannulation after TAVI with SE devices and commissural alignment: the REACCESS-2 study
One-year outcomes from the ACURATE neo2 PMCF post-market registry
Preliminary study of a new pre-mounted ready-to-use balloon-expandable transcatheter heart valve
Improved haemodynamics of latest generation balloon-expandable Sapien-3 Ultra RESILIA valve
DurAVR biomimetic transcatheter heart valve: results from the first-in-human and US early feasibility studies

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

Late-breaking trials on latest-generation aortic valves and dedicated transcatheter devices

Session comprising selected PCR London Valves 2023 Late-Breaking Trial submissions

Log in or create account for free